The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1756-8722
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib ; volume:2 ; number:1 ; day:12 ; month:11 ; year:2009 ; pages:1-6 ; date:12.2009
Journal of hematology & oncology ; 2, Heft 1 (12.11.2009), 1-6, 12.2009
- Urheber
-
Masiello, David
Gorospe, Gerry
Yang, Allen S.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/1756-8722-2-46
- URN
-
urn:nbn:de:101:1-2021082108382997696600
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 14.08.2025, 10:49 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Masiello, David
- Gorospe, Gerry
- Yang, Allen S.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Incidence of pleural effusion with dasatinib and the effect of switching therapy to a different TKI in patients with chronic phase CML
Quantitative prediction of long-term molecular response in TKI-treated CML – Lessons from an imatinib versus dasatinib comparison
BCAT1 contributes to the development of TKI-resistant CML
Ascites does not accompany pleural effusion developing under dasatinib therapy in patients with CML-CP
New dosing schedules of dasatinib for CML and adverse event management
TKi | TKi
Is There a Role for Dose Modification of TKI Therapy in CML?
Knockout of LASP1 in CXCR4 expressing CML cells promotes cell persistence, proliferation and TKI resistance
TKI
TKI
TKi
TKi
Incidence of pleural effusion with dasatinib and the effect of switching therapy to a different TKI in patients with chronic phase CML
Quantitative prediction of long-term molecular response in TKI-treated CML – Lessons from an imatinib versus dasatinib comparison
BCAT1 contributes to the development of TKI-resistant CML
Ascites does not accompany pleural effusion developing under dasatinib therapy in patients with CML-CP
New dosing schedules of dasatinib for CML and adverse event management
TKi | TKi
Is There a Role for Dose Modification of TKI Therapy in CML?
Knockout of LASP1 in CXCR4 expressing CML cells promotes cell persistence, proliferation and TKI resistance
TKI
TKI
TKi
TKi
Incidence of pleural effusion with dasatinib and the effect of switching therapy to a different TKI in patients with chronic phase CML
Quantitative prediction of long-term molecular response in TKI-treated CML – Lessons from an imatinib versus dasatinib comparison
BCAT1 contributes to the development of TKI-resistant CML
Ascites does not accompany pleural effusion developing under dasatinib therapy in patients with CML-CP
New dosing schedules of dasatinib for CML and adverse event management
TKi | TKi
Is There a Role for Dose Modification of TKI Therapy in CML?
Knockout of LASP1 in CXCR4 expressing CML cells promotes cell persistence, proliferation and TKI resistance
TKI
TKI
TKi